• Coronado Biosciences Inc., of Burlington, Mass., said it initiated a National Institutes of Health-sponsored Phase II study evaluating TSO (Trichuris suis ova, CNDO-201) for the treatment of ulcerative colitis (UC). Read More
• Celator Pharmaceuticals Inc., of Ewing, N.J., said it was approved for quotation on the OTC Bulletin Board and OTC Market Group’s OTC Link quotation system under the ticker “CLPM.” Read More
• Egalet Ltd., of Malvern, Pa., closed a financing of up to $20 million led by Index Ventures with participation from other existing investors. Read More
Scientists have reported that monkeys that received a vaccine against simian immunodeficiency virus, the monkey version of HIV, were able to first control and ultimately clear their infections, even after the type of viral reservoir had developed that bedevils the ability of highly active antiretroviral therapy (HAART) to truly get rid of HIV. Read More
Virtual biotech Jenrin Discovery LLC spent its first six years targeting peripherally selective (PS) CB1 receptor antagonists as a safer and more effective approach to treat diabetes and other metabolic disorders. Read More
A great deal has transpired in the antibiotics world since the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) last convened one year ago. As researchers and antibiotic drug developers alike meet in Denver this week for the annual meeting, the focus is squarely on new product pipeline progress and whether those innovative products nearing the marketplace will be enough to alleviate the growing concern about multidrug resistance in virulent bacteria. Read More
Shares of Zealand Pharma A/S dropped 15.4 percent Thursday after lixisenatide partner Sanofi SA said it decided to withdraw its new drug application (NDA) for the once-daily glucagon-like peptide-1 (GLP-1) receptor agonist in Type II diabetes mellitus, with plans to resubmit in 2015 after completing a cardiovascular outcomes trial. Read More
As approved prostate cancer drugs duke it out in the prostate cancer space and scramble for pre-chemotherapy patients, Bristol-Myers Squibb Co.’s near-miss Phase III results with the anti-CTLA-4 drug Yervoy (ipilimumab) in advanced disease left some cause in the data for optimism that the melanoma therapy might fare better in a separate trial against earlier stages of the tumor. Read More
• Breckenridge Pharmaceutical Inc., of Boca Raton, Fla., said it completed its acquisition of certain Cypress Pharmaceutical Inc. product assets from Pernix Therapeutics Inc., of The Woodlands, Texas, including 11 abbreviated new drug applications (ANDAs) filed with the FDA, certain ANDAs in various stages of development, as well as six already-approved and marketed products. Read More
